The Putative Oncoprotein Bcl-3 Induces Cyclin D1 To Stimulate G₁ Transition

REFERENCES

• Albanese, C., G. Johnson, N. Watanabe, N. Eklund, D. Vu, A. Arnold, and R. G. Pestell. 1995. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270:23589–23597.
   PubMed Web of Science ®Google Scholar
• Baldwin, A. S. Jr.. 1996. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649–683.
   PubMed Web of Science ®Google Scholar
• Beijersbergen, R. L., and R. Bernards. 1996. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim. Biophys. Acta 1287:103–120.
   PubMed Web of Science ®Google Scholar
• Bours, V., G. Franzoso, V. Azarenko, S. Park, T. Kanno, K. Brown, and U. Siebenlist. 1993. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72:729–739.
   PubMed Web of Science ®Google Scholar
• Brasier, A. R., M. Lu, T. Hai, Y. Lu, and I. Boldogh. 2001. NF-κB inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-κB1 residence. J. Biol. Chem. 276:32080–32093.
   PubMed Web of Science ®Google Scholar
• Cogswell, P. C., D. C. Guttridge, W. K. Funkhouser, and A. S. Baldwin Jr.. 2000. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene 19:1123–1131.
   PubMed Web of Science ®Google Scholar
• Dechend, R., F. Hirano, K. Lehmann, V. Heissmeyer, S. Ansieau, F. Wulczyn, C. Scheidereit, and A. Leutz. 1999. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene 18:3316–3323.
   PubMed Web of Science ®Google Scholar
• Feng, X., Y. Jiang, P. Meltzer, and P. M. Yen. 2001. Transgenic targeting of a dominant negative corepressor to liver blocks basal repression by the thyroid hormone receptor and increases cell proliferation. J. Biol. Chem. 276:15066–15072.
   PubMedGoogle Scholar
• Franzoso, G., V. Bours, S. Park, M. Tomita-Yamaguchi, K. Kelly, and U. Siebenlist. 1992. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-κB-mediated inhibition. Nature 359:339–342.
   PubMedGoogle Scholar
• Fujita, T., G. P. Nolan, H. C. Liou, M. L. Scott, and D. Baltimore. 1993. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev. 7:1354–1363.
   PubMed Web of Science ®Google Scholar
• Ghosh, S., M. J. May, and E. B. Kopp. 1998. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:225–260.
   PubMed Web of Science ®Google Scholar
• Guttridge, D. C., C. Albanese, J. Y. Reuther, R. G. Pestell, and A. S. Baldwin Jr.. 1999. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19:5785–5799.
   PubMed Web of Science ®Google Scholar
• Hinz, M., D. Krappmann, A. Eichten, A. Heder, C. Scheidereit, and M. Strauss. 1999. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19:2690–2698.
   PubMed Web of Science ®Google Scholar
• Joyce, D., B. Bouzahzah, M. Fu, C. Albanese, M. D'Amico, J. Steer, J. U. Klein, R. J. Lee, J. E. Segall, J. K. Westwick, C. J. Der, and R. G. Pestell. 1999. Integration of Rac-dependent regulation of cyclin D1 transcription through a NF-κB-dependent pathway. J. Biol. Chem. 274:25245–25249.
   PubMed Web of Science ®Google Scholar
• Kalejta, R. F., T. Shenk, and A. J. Beavis. 1997. Use of a membrane-localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry. Cytometry 29:286–291.
   PubMedGoogle Scholar
• La Thangue, N. B.. 1994. DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem. Sci. 19:108–114.
   PubMed Web of Science ®Google Scholar
• Lee, R. J., C. Albanese, M. Fu, M. D'Amico, B. Lin, G. Watanabe, G. K. Haines III, P. M. Siegel, M. C. Hung, Y. Yarden, J. M. Horowitz, W. J. Muller, and R. G. Pestell. 2000. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol. 20:672–683.
   PubMed Web of Science ®Google Scholar
• Mayo, M. W., J. L. Norris, and A. S. Baldwin. 2001. Ras regulation of NF-κB and apoptosis. Methods Enzymol. 333:73–87.
   PubMedGoogle Scholar
• Mayo, M. W., C. Y. Wang, P. C. Cogswell, K. S. Rogers-Graham, S. W. Lowe, C. J. Der, and A. S. Baldwin Jr.. 1997. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278:1812–1815.
   PubMed Web of Science ®Google Scholar
• McKeithan, T. W., J. D. Rowley, T. B. Shows, and M. O. Diaz. 1987. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 84:9257–9260.
   PubMed Web of Science ®Google Scholar
• McKeithan, T. W., G. S. Takimoto, H. Ohno, V. S. Bjorling, R. Morgan, B. K. Hecht, I. Dube, A. A. Sandberg, and J. D. Rowley. 1997. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. Genes Chromosomes Cancer 20:64–72.
   PubMed Web of Science ®Google Scholar
• Na, S. Y., H. S. Choi, J. W. Kim, D. S. Na, and J. W. Lee. 1998. Bcl3, an IκB protein, as a novel transcription coactivator of the retinoid X receptor. J. Biol. Chem. 273:30933–30938.
   PubMedGoogle Scholar
• Na, S. Y., J. E. Choi, H. J. Kim, B. H. Jhun, Y. C. Lee, and J. W. Lee. 1999. Bcl3, an IκB protein, stimulates activating protein-1 transactivation and cellular proliferation. J. Biol. Chem. 274:28491–28496.
   PubMedGoogle Scholar
• Nakshatri, H., P. Bhat-Nakshatri, D. A. Martin, R. J. Goulet Jr., and G. W. Sledge Jr.. 1997. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17:3629–3639.
   PubMed Web of Science ®Google Scholar
• Nolan, G. P., T. Fujita, K. Bhatia, C. Huppi, H.-C. Liou, M. L. Scott, and D. Baltimore. 1993. The bcl-3 proto-oncogene encodes a nuclear IκB-like molecule that preferentially interacts with NF-κB p50 and p52 in a phosphorylation-dependent manner. Mol. Cell. Biol. 13:3557–3566.
   PubMedGoogle Scholar
• Ohno, H., S. Doi, K. Yabumoto, S. Fukuhara, and T. W. McKeithan. 1993. Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia. Leukemia 7:2057–2063.
   PubMed Web of Science ®Google Scholar
• Ong, S. T., M. L. Hackbarth, L. C. Degenstein, D. A. Baunoch, J. Anastasi, and T. W. McKeithan. 1998. Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice. Oncogene 16:2333–2343.
   PubMed Web of Science ®Google Scholar
• Pan, J., and R. P. McEver. 1995. Regulation of the human P-selectin promoter by Bcl-3 and specific homodimeric members of the NF-κB/Rel family. J. Biol. Chem. 270:23077–23083.
   PubMed Web of Science ®Google Scholar
• Rebollo, A., L. Dumoutier, J.-C. Renauld, A. Zaballos, V. Ayllón, and C. Martinez-A. 2000. Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors. Mol. Cell. Biol. 20:3407–3416.
   PubMedGoogle Scholar
• Richard, M., J. Louahed, J. B. Demoulin, and J. C. Renauld. 1999. Interleukin-9 regulates NF-κB activity through BCL3 gene induction. Blood 93:4318–4327.
   PubMedGoogle Scholar
• Sherr, C. J.. 1996. Cancer cell cycles. Science 274:1672–1677.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J.. 1993. Mammalian G1 cyclins. Cell 73:1059–1065.
   PubMed Web of Science ®Google Scholar
• Sicinski, P., J. L. Donaher, S. B. Parker, T. Li, A. Fazeli, H. Gardner, S. Z. Haslam, R. T. Bronson, S. J. Elledge, and R. A. Weinberg. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621–630.
   PubMed Web of Science ®Google Scholar
• Sovak, M. A., R. E. Bellas, D. W. Kim, G. J. Zanieski, A. E. Rogers, A. M. Traish, and G. E. Sonenshein. 1997. Aberrant NF-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Investig. 100:2952–2960.
   PubMed Web of Science ®Google Scholar
• Wang, D., and A. S. Baldwin Jr.. 1998. Activation of NF-κB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273:29411–29416.
   PubMedGoogle Scholar
• Wang, T. C., R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt. 1994. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669–671.
   PubMed Web of Science ®Google Scholar
• Weinstat-Saslow, D., M. J. Merino, R. E. Manrow, J. A. Lawrence, R. F. Bluth, K. D. Wittenbel, J. F. Simpson, D. L. Page, and P. S. Steeg. 1995. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1:1257–1260.
   PubMed Web of Science ®Google Scholar
• Wulczyn, F. G., M. Naumann, and C. Scheidereit. 1992. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-κB. Nature 358:597–599.
   PubMedGoogle Scholar
• Yu, Q., Y. Geng, and P. Sicinski. 2001. Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017–1021.
   PubMed Web of Science ®Google Scholar
• Zhang, M. Y., E. W. Harhaj, L. Bell, S. C. Sun, and B. A. Miller. 1998. Bcl-3 expression and nuclear translocation are induced by granulocyte-macrophage colony-stimulating factor and erythropoietin in proliferating human erythroid precursors. Blood 92:1225–1234.
   PubMedGoogle Scholar
• Zhang, Q., J. A. Didonato, M. Karin, and T. W. McKeithan. 1994. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-κB proteins. Mol. Cell. Biol. 14:3915–3926.
   PubMed Web of Science ®Google Scholar